Home Tags Tisotumab Vedotin

Tag: Tisotumab Vedotin

Seagen Presents Broad Portfolio of Innovative Immuno-Oncology Data – Featuring Sugar-Engineered...

During the upcoming 35th annual meeting of the Society for Immunotherapy of Cancer’s (SITC) being held November 9-14, 2020, Seagen (previously known as Seattle...

ESMO 2020: Study Shows Meaningful Clinical Activity with Tisotumab Vedotin ...

Tisotumab vedotin, an investigational agent is being developed by Seattle Genetics and Genmab, shows meaningful clinical activity as monotherapy in patients with previously treated...
Featured Image: Genmab's bioreactor laboratory. Photo Courtesy: 2020 Genmab.

Positive Phase II Trial Results for Tisotumab Vedotin Cervical Cancer

The phase II innovaTV 204 trial, a single-arm clinical trial also known as GCT1015-04 or GOG-3023/ENGOT-cx6 (NCT03438396), evaluating tisotumab vedotin administered every three weeks...
Featured Image: Annual Congress of ESMO 2018. Courtesy: © 2018 European Society for Medical Oncology. Used with permission.

ESMO 2019: Seattle Genetics to Present Initial Data from a Phase...

Less than a week before the start of the annual meeting of the European Society for Medical Oncology (ESMO), to be held September 27...

Phase II Trial of Tisotumab Vedotin in Advanced Cervical Cancer Provides...

Genmab and Seattle Genetics confirmed their decision to start a Phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer....

Tisotumab vedotin Demonstrates Encouraging Response Rate and a Manageable Safety Profile...

Preliminary clinical data for tisotumab vedotin, also known as HuMax®-TF-ADC from a Genmab-sponsored phase I/II clinical trial (GEN 701) were featured today in an...